MedTrace Logo

Omnifit Hydroxylapatite (HA) Hip Outcomes Study

NCT00958347 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 226

Last updated 2014-08-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to obtain up to 25 year post-operative data on the Omnifit Hydroxylapatite (HA) Hip System in support of the hypothesis that it is a satisfactory system for reducing implant loosening, permitting tissue bonding onto the hydroxylapatite surfaces of the implant and providing a safe, efficient, and well-functioning hip in a wide spectrum of clinical circumstances.

Conditions

  • Arthroplasty, Replacement, Hip

Interventions

DEVICE

Omnifit HA Hip Stem

Total Hip Replacement with Omnifit HA Hip Stem

Sponsors & Collaborators

  • Stryker Orthopaedics

    lead INDUSTRY

Principal Investigators

  • William Capello, MD · Indiana University School of Medicine

  • William Jaffe, MD · Hospital for Joint Disease/ Orthopaedic Institute

  • Rudolph Geesink, MD · Trialbureau Orthopedics

  • James D'Antonio, MD · Sewickley Valley Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1987-10-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United States
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00958347 on ClinicalTrials.gov